Troy Rafferty Instrumental in $80 Million Settlement for Plaintiffs in Actos Litigation
Settlement for Plaintiffs in Actos Litigation
In another powerful victory for consumers harmed by dangerous drugs, Troy Rafferty, shareholder at Rafferty Domnick Cunningham & Yaffa, played a central role in negotiating an $80 million settlement for plaintiffs in the Actos litigation, providing justice and compensation to individuals diagnosed with bladder cancer after taking the widely used diabetes medication.
The settlement brings resolution to thousands of cases against the manufacturer, Takeda Pharmaceuticals, which faced claims that it failed to warn patients and healthcare providers about the serious cancer risks associated with long-term use of Actos (pioglitazone).
